CST, 63691S, Exo2

Product Usage Information
Exo2 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 0.94 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
Exo2 is a small-molecule inhibitor of secretion and retrograde trafficking in cells. Exo2 stimulates morphological changes at the mammalian Golgi and trans-Golgi network, fusing the endoplasmic reticulum (ER) and Golgi apparatus. These morphological changes prevent the release of secretory cargo from the ER and disrupts the Golgi apparatus. Exo2 also perturbs the retrograde transport of Shiga toxin to the ER (1). Chemical modification of the secretion inhibitor Exo2 has produced a host of useful Exo2 analogs, capable of distinguishing differences in organelle morphology, target specificity, innate toxicity, and toxin protection (2). In a study of Arabidopsis root epidermal cells, Exo2 had no significant effect on organelle morphology, while an Exo2 derivative (LG8) induced severe morphological alterations in both the Golgi and the ER (3).
Alternate Names
2-Methoxy-4-[(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-hydrazonomethyl]- phenol